Abstract

BackgroundVancomycin resistant enterococci (VRE) are on the rise in many European hospitals. In 2018, Switzerland experienced its largest nosocomial VRE outbreak. The national center for infection prevention (Swissnoso) elaborated recommendations for controlling this outbreak and published guidelines to prevent epidemic and endemic VRE spread. The primary goal of this study was to evaluate adherence to this new guideline and its potential impact on the VRE epidemiology in Swiss acute care hospitals.MethodsIn March 2020, Swissnoso distributed a survey among all Swiss acute care hospitals. The level of adherence as well as changes of infection prevention and control (IPC) strategies in the years 2018 and 2019 after publication of the national guidelines were asked along with an inventory on VRE surveillance and outbreaks.ResultsData of 97/146 (66%) participants were available, representing 81.6% of all acute care beds operated in Switzerland in 2019. The vast majority—72/81 (88%) responding hospitals—have entirely or largely adopted our new national guideline. 38/51 (74.5%) hospitals which experienced VRE cases were significantly more likely to have changed their IPC strategies than those 19/38 (50%) hospitals without VRE cases p = 0.017). The new IPC guidelines included (1) introduction of targeted admission screening in 89.5%, (2) screening of close contacts of VRE cases in 56%, and (3) contact precaution for suspected VRE cases 58% of these hospitals. 52 (54%) hospitals reported 569 new VRE cases in 2018 including 14 bacteremia, and 472 new cases in 2019 with 10 bacteremia. The ten largest outbreaks encountered between 2018 and 2019 included 671 VRE cases, of which most (93.4%) consisted of colonization events, 29 (4.3%) infections and 15 (2.2%) bacteremia.ConclusionWide adoption of this VRE control guideline seemed to have a positive effect on VRE containment in Swiss acute care hospitals over two years, even if its long-term impact on the VRE epidemiology remains to be evaluated. Broad dissemination and strict implementation of a uniform national guideline may therefore serve as model for other countries to fight VRE epidemics on a national level.

Highlights

  • Vancomycin resistant enterococci (VRE) are increasing in many European countries

  • In addition to the mandatory reporting, Swissnoso made use of the systematic surveillance implemented by the national center of antibiotic resistance (ANRESIS) and started publishing quarterly data on new VRE cases reported to this platform [21]

  • The participants indicated to serve a total of 22,106 beds, which is 81.6% of all acute care beds operated in Switzerland in 2019 according to the Swiss Federal Office of Public Health [25]

Read more

Summary

Introduction

Vancomycin resistant enterococci (VRE) are increasing in many European countries. In their last annual epidemiological report, the European Center for Disease Control and Prevention has issued a statement of Vuichard‐Gysin et al Antimicrobial Resistance & Infection Control (2022) 11:19 concern [1]. In 2018, the Federal Office of Public Health (FOPH) commissioned Swissnoso, the Swiss Center for Infection Prevention, to investigate a large countrywide nosocomial outbreak of VRE affecting several hospitals with spill-over into many other cantons [2]. This investigation revealed gaps in national surveillance and communication between hospitals and public health authorities. There is no evidence from any European country, that current strains of VRE and clonal complexes that are endemic in healthcare settings, have started to circulate in the community [5]. The primary goal of this study was to evaluate adherence to this new guideline and its potential impact on the VRE epidemiology in Swiss acute care hospitals

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call